3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Breast
1
Conditions
Lymphoma, Large B-Cell, Diffuse
18
Sarcoma
15
Burkitt Lymphoma
9
Breast Neoplasms
9
Precursor Cell Lymphoblastic Leukemia-Lymphoma
8
Neoplasm Metastasis
8
Triple Negative Breast Neoplasms
7
Lymphoma, T-Cell, Peripheral
7
Lymphoma, Follicular
7
Lymphoma, B-Cell
7
Ovarian Neoplasms
6
Lymphoma
6
Hodgkin Disease
6
Endometrial Neoplasms
5
Osteosarcoma
4
Neuroblastoma
4
Lymphoma, Non-Hodgkin
4
Liposarcoma
4
Recurrence
3
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
3
Peritoneal Neoplasms
3
Neoplasms
3
Leukemia, Biphenotypic, Acute
3
Leiomyosarcoma
3
Histiocytoma, Malignant Fibrous
3
Hemangiosarcoma
3
Colorectal Neoplasms
3
Uterine Neoplasms
2
Stomach Neoplasms
2
Sarcoma, Synovial
2
Interventions
Carboplatin
4
pertuzumab
2
durvalumab
2
Tretinoin
2
Trastuzumab
2
Standard of Care
2
Paclitaxel
2
Oxaliplatin
2
zanidatamab
1
veliparib
1
tucatinib
1
trilaciclib
1
trebananib
1
trastuzumab duocarmazine
1
toripalimab
1
tislelizumab
1
talazoparib
1
sarilumab
1
relugolix
1
regorafenib
1
pexidartinib
1
pembrolizumab
1
patritumab
1
olaparib
1
niraparib
1
nimotuzumab
1
neratinib
1
ganitumab
1
enzalutamide
1
dostarlimab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Pathologic Complete Response
×
Doxorubicin
×
Clear all
NCT01042379
2026-05-06
I-SPY
QuantumLeap Healthcare Collaborative
Phase 2
Recruiting
5,000 enrolled